SAWAI GROUP HOLDINGS Co.,Ltd. held a briefing for individual investors on 16 September 2026, featuring Senior Executive Officer Nakate Toshiomi (中手 利臣), who was appointed in April. The company presented an overview of its FY2026 results, plans to expand production capacity and its dividend policy.
SAWAI GROUP HOLDINGS Co.,Ltd. reiterated its business model centered on generic drugs and announced revenue of ¥201.7 billion and operating profit of ¥15.9 billion for the fiscal year ending March 2026. Sales volume reached 17.1 billion tablets, equivalent to approximately 140 tablets per person in Japan per year, or 1 tablet every 3 days. Senior Executive Officer Nakate Toshiomi (中手 利臣), who became president in April, spoke at the briefing.
In its core generic drugs business, the company said production volume would increase to 22 billion tablets in FY2026 following the launch of a new building at the second Kyushu plant, supported by production capacity at its 8 plants in Japan, and that it aims to establish a 25-billion-tablet production system by FY2030. The FY2026 plan calls for revenue of ¥208.4 billion and production volume of 18 billion tablets, with approximately 700 products. The product mix comprises cardiovascular drugs at 27.0%, central nervous system drugs at 16.2% and gastrointestinal drugs at 15.7%; the company is also expanding its coverage of lifestyle-related diseases.
The company also explained its efforts to improve ease of administration and dispensing through its formulation technology brand “SAWAI HARMOTECH,” its approximately 370 MR personnel and its ability to provide information through a contact center handling approximately 42,600 inquiries annually. Shareholder returns are based on a target DOE of at least 3.0%. The annual dividend for FY2026 is expected to be ¥56, an increase of ¥1 from the previous fiscal year, implying a dividend yield of approximately 3.5%. No shareholder benefits are planned.